White House
Deputy Director, White House Domestic Policy Council · Trump-announced FDA nominee
Newest first
The U.S. Office of Personnel Management identifies Overton as Deputy Director of the White House Domestic Policy Council. Her earlier White House service includes the 2019–2020 White House Fellows program.
Open this record ↓President Trump publicly named Dr. Heidi Overton, deputy director of the White House Domestic Policy Council, as his choice to lead the Food and Drug Administration on August 19. Reuters and AP reported Trump’s announcement. Senate confirmation is required; TrumpsMouth did not locate a formal nomination-transmission entry in the White House nominations index or Senate nomination records reviewed at this update, so the record does not treat her as confirmed or already serving as FDA commissioner.
Open canonical evidence record →President Trump publicly named Dr. Heidi Overton as his choice to lead the Food and Drug Administration. Reuters and AP report that Senate confirmation is required. This profile keeps the announced choice, formal nomination transmission, Senate action and assumption of office as separate procedural stages.
Open this record ↓No records on this profile currently match that subject.
Dr. Heidi Overton is a physician and Deputy Director of the White House Domestic Policy Council. President Trump publicly named her on August 19, 2026 as his choice to lead the Food and Drug Administration; Senate confirmation is required before she can serve as commissioner.
Overton previously served as a 2019–2020 White House Fellow and later as Chief Policy Officer and Vice Chair of the Center for a Healthy America at the America First Policy Institute. Federal and archived White House records document her earlier policy and medical background.
TrumpsMouth treats the FDA transition as a staged public-record process: announced presidential choice, formal nomination transmission, Senate consideration, confirmation, and assumption of office are recorded separately when each occurs.
This profile distinguishes Overton’s current White House role, Trump’s announced FDA choice, any later formal nomination paperwork, Senate confirmation proceedings, and assumption of office. Criticism or support for her policy views is attributed to the relevant source rather than treated as a factual verdict.
